Compare Gold Fields Limited (GFI) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Incyte Corporation — how do they compare? Gold Fields Limited trades at $32.28 (market cap $29.07B), while Incyte Corporation trades at $115.78 (market cap $22.99B). The key difference: Gold Fields Limited is the larger of the two by market cap, and Gold Fields Limited pays a 7.03% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| GFI | INCY | |
|---|---|---|
Market Cap | $29.07B | $22.99B |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $118.52 |
52-Week Low | $23.95 | $67.38 |
Enterprise Value | $30.51B | $19.01B |
Dividend Yield | 7.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $32.28, down 3.15% today, amid a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 40.76% net income margin and 52.33% ROE, while valuation ratios like P/E of 8.37 suggest undervaluation. Recent earnings were mixed, with a Q1 2025 beat but Q2 and Q4 2025 misses, and cash flow trends improved significantly in 2025 projections. News highlights operational challenges from inflation and geopolitical factors, though long-term value arguments persist.
The outlook balances deep value against near-term headwinds. Analyst consensus leans bullish with a $52.75 price target, but technical weakness and cost pressures pose risks. Investment appeal hinges on execution of production targets and gold price stability, with high ROE supporting shareholder returns.
INCY trades at $115.83, up 0.83% today, with a bullish technical signal from moving averages and strong fundamental performance including 2025 revenue of $5.14B and net income of $1.29B. Recent developments include positive Phase 1/2 data for VGA039 presented at ISTH 2026 and the acquisition of Vega Therapeutics, expanding its hematology portfolio. The stock shows robust profitability with a 26.71% net income margin and 30.82% ROE, while analyst consensus is a Buy with a $112.78 price target.
Outlook remains positive driven by pipeline advancements and earnings growth, though risks include clinical trial outcomes and regulatory hurdles. The current price above the consensus target suggests limited near-term upside, but continued execution could support further gains. Investors should weigh strong cash flow generation against competitive pressures in the biopharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
